Research programme: melanin inhibitors - Anaderm
Latest Information Update: 05 Sep 2006
At a glance
- Originator Anaderm Research
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Melanosis
Most Recent Events
- 05 Sep 2006 Discontinued - Preclinical for Melanosis in USA (Topical)
- 03 Oct 2001 Preclinical development for Melanosis in USA (Topical)